Natera ( (NTRA) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Natera’s stock has experienced unusual movements following the company’s announcement of successfully enrolling over 1,600 patients in the EXPAND trial. Additionally, a study published in the Journal of Clinical Oncology highlighted the potential of Signatera as a prognostic biomarker for germ cell tumors, sparking increased interest. As a result, analysts have raised the company’s price target, driven by the promising trial results and the validation study of Signatera.
More about Natera
YTD Price Performance: 0.23%
Average Trading Volume: 1,266,129
Technical Sentiment Signal: Strong Buy
Current Market Cap: $22.38B
For further insights into NTRA stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.